Greenhouse Funds LLLP Grows Stock Position in Phreesia, Inc. $PHR

Greenhouse Funds LLLP grew its position in shares of Phreesia, Inc. (NYSE:PHR) by 12.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,325,262 shares of the company’s stock after purchasing an additional 368,352 shares during the period. Phreesia comprises about 3.9% of Greenhouse Funds LLLP’s holdings, making the stock its 8th largest holding. Greenhouse Funds LLLP owned approximately 5.59% of Phreesia worth $94,637,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new stake in Phreesia in the first quarter worth approximately $774,000. Farther Finance Advisors LLC lifted its holdings in shares of Phreesia by 9,375.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock worth $86,000 after acquiring an additional 3,000 shares during the last quarter. Arcadia Investment Management Corp MI boosted its stake in shares of Phreesia by 22.3% in the 2nd quarter. Arcadia Investment Management Corp MI now owns 113,470 shares of the company’s stock valued at $3,229,000 after purchasing an additional 20,700 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Phreesia by 105.2% during the 1st quarter. Acadian Asset Management LLC now owns 225,317 shares of the company’s stock valued at $5,754,000 after purchasing an additional 115,527 shares during the last quarter. Finally, Deutsche Bank AG raised its position in Phreesia by 30.6% in the 1st quarter. Deutsche Bank AG now owns 74,857 shares of the company’s stock worth $1,913,000 after purchasing an additional 17,560 shares during the period. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Phreesia Trading Up 0.8%

Shares of NYSE PHR opened at $20.17 on Wednesday. Phreesia, Inc. has a 1 year low of $18.55 and a 1 year high of $32.76. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.12 and a quick ratio of 2.12. The firm has a 50-day moving average of $22.28 and a 200 day moving average of $25.38. The stock has a market cap of $1.21 billion, a P/E ratio of -48.02 and a beta of 0.74.

Phreesia (NYSE:PHR) last announced its earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.08. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The business had revenue of $117.26 million during the quarter, compared to the consensus estimate of $116.39 million. During the same quarter last year, the firm earned ($0.03) earnings per share. The business’s revenue for the quarter was up 14.9% on a year-over-year basis. As a group, sell-side analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PHR has been the topic of a number of recent research reports. Stephens reaffirmed an “overweight” rating and set a $32.00 price objective on shares of Phreesia in a research note on Wednesday, September 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Phreesia in a research report on Friday, October 31st. Canaccord Genuity Group lifted their price target on Phreesia from $34.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, September 5th. Piper Sandler increased their price objective on Phreesia from $33.00 to $34.00 and gave the company an “overweight” rating in a research note on Friday, September 5th. Finally, JMP Securities raised their target price on shares of Phreesia from $30.00 to $34.00 and gave the stock a “market outperform” rating in a report on Monday, September 8th. Fourteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $33.86.

Insider Buying and Selling at Phreesia

In other Phreesia news, insider David Linetsky sold 2,165 shares of the business’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total value of $50,401.20. Following the sale, the insider directly owned 174,952 shares of the company’s stock, valued at approximately $4,072,882.56. The trade was a 1.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Allison C. Hoffman sold 3,133 shares of the firm’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total value of $72,936.24. Following the transaction, the general counsel owned 139,037 shares of the company’s stock, valued at $3,236,781.36. The trade was a 2.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 26,174 shares of company stock valued at $603,835 in the last ninety days. Corporate insiders own 5.50% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.